Characteristics | LMR < 2.8 (n = 42) | LMR≥ 2.8 (n = 97) | P value |
Age (years) <60 ≥60 |
28 (66.7%) 14 (33.3%) |
78 (80.4%) 19 (19.6%) | 0.08 |
Sex Male Female |
26 (61.9%) 16 (38.1%) |
56 (57.7%) 41 (42.3%) | 0.64 |
ECOG PS 0 1 2 |
6 (14.3%) 24 (57.1%) 12 (28.6%) |
34 (35.%1) 50 (51.5%) 13 (13.4%) | 0.01 |
Extra-nodal sites >1 ≤1 |
10 (23.8%) 32 (76.2%) |
53 (54.6%) 44 (45.4%) | 0.001* |
Ann Arbor stage I II III IV |
1 (2.4%) 7 (16.7%) 23 (54%.8) 11 (26.2%) |
3 (3.1 %) 34 (35.1%) 40 (41.2%) 20 (20.6%) | 0.086 |
IPI 0 1 2 3 4 5 |
1 (2.4%) 1 (2.4%) 11 (26.2%) 21 (50%) 7 (16.7%) 1 (2.4%) |
14 (14.4%) 19 (19.6%) 29 (29.9%) 34 (35.1%) 1 (1%) 0 (0.0%) | <0.001* |
Treatment R-CHOP CHOP |
4 (9.5%) 38 (90.5%) |
31 (32%) 66 (68%) | 0.005 |
Following completion of therapy ALC AMC |
1025 (770 - 1430) 490 (280 - 680) |
1320 (1100 - 1870) 310 (200 - 650) |
<0.001* <0.001* |
Following completion of therapy LDH Normal >Normal |
16 (38.1%) 26 (61.9%) |
75 (77.3%) 22 (22.7%) |
<0.001* |
State of disease Follow up Relapsed |
5 (11.9%) 37 (88.1%) |
95 (97.9%) 2 (2.1%) |
<0.001* |